Mischel PS - Search Results

1

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK. Vivanco I, et al. Among authors: mischel ps. Cancer Discov. 2012 May;2(5):458-71. doi: 10.1158/2159-8290.CD-11-0284. Epub 2012 Mar 31. Cancer Discov. 2012. PMID: 22588883 Free PMC article.

2

Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.

Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV, Cloughesy TF, Mischel PS. Choe G, et al. Among authors: mischel ps. Clin Cancer Res. 2002 Sep;8(9):2894-901. Clin Cancer Res. 2002. PMID: 12231534

3

Targeted molecular therapy of GBM.

Mischel PS, Cloughesy TF. Mischel PS, et al. Brain Pathol. 2003 Jan;13(1):52-61. doi: 10.1111/j.1750-3639.2003.tb00006.x. Brain Pathol. 2003. PMID: 12580545 Free PMC article. Review.

4

Identification of molecular subtypes of glioblastoma by gene expression profiling.

Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF. Mischel PS, et al. Oncogene. 2003 Apr 17;22(15):2361-73. doi: 10.1038/sj.onc.1206344. Oncogene. 2003. PMID: 12700671

5

Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.

Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS. Choe G, et al. Among authors: mischel ps. Cancer Res. 2003 Jun 1;63(11):2742-6. Cancer Res. 2003. PMID: 12782577

6

Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy.

Mischel PS, Nelson SF, Cloughesy TF. Mischel PS, et al. Cancer Biol Ther. 2003 May-Jun;2(3):242-7. doi: 10.4161/cbt.2.3.369. Cancer Biol Ther. 2003. PMID: 12878856 Review.

7

Gene expression profiling identifies molecular subtypes of gliomas.

Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, Mischel PS, Nelson SF. Shai R, et al. Among authors: mischel ps. Oncogene. 2003 Jul 31;22(31):4918-23. doi: 10.1038/sj.onc.1206753. Oncogene. 2003. PMID: 12894235

8

p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.

Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. Wang Y, et al. Among authors: mischel ps. Oncogene. 2004 Feb 12;23(6):1283-90. doi: 10.1038/sj.onc.1207244. Oncogene. 2004. PMID: 14961077

9

Gene expression profiling of gliomas strongly predicts survival.

Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF. Freije WA, et al. Among authors: mischel ps. Cancer Res. 2004 Sep 15;64(18):6503-10. doi: 10.1158/0008-5472.CAN-04-0452. Cancer Res. 2004. PMID: 15374961

10

DNA-microarray analysis of brain cancer: molecular classification for therapy.

Mischel PS, Cloughesy TF, Nelson SF. Mischel PS, et al. Nat Rev Neurosci. 2004 Oct;5(10):782-92. doi: 10.1038/nrn1518. Nat Rev Neurosci. 2004. PMID: 15378038 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

250 results

Search Page